Back to top
more

Intuitive Surgical (ISRG)

(Real Time Quote from BATS)

$515.93 USD

515.93
330,848

+8.51 (1.68%)

Updated Nov 5, 2024 10:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Luminex (LMNX) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Higher revenues and solid performance across System Sales, Consumable Sales and Royalty Revenues benefit Luminex's (LMNX) Q2 earnings. However, gross margin contraction remains a woe.

CONMED (CNMD) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q2 earnings. However, high long-term debt remains a concern.

ABIOMED (ABMD) Q1 Earnings Top Estimates, Sales Rise in Japan

by Zacks Equity Research

ABIOMED (ABMD) slashes revenue guidance for fiscal 2020.

Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ISRG) Outperforming Other Medical Stocks This Year?

IDEXX (IDXX) Beats Q2 Earnings Estimates, Lifts EPS Guidance

by Zacks Equity Research

IDEXX's (IDXX) top line in the second quarter gains from strong sales at the CAG business.

Surmodics (SRDX) Q3 Earnings Beat Estimates, Guidance Raised

by Zacks Equity Research

Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q3.

Masimo (MASI) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research

Buoyed by a solid second quarter, Masimo (MASI) raises its 2019 guidance.

Fresenius Medical (FMS) Q2 Earnings Miss Estimates, Down Y/Y

by Zacks Equity Research

Strong segmental performance and solid 2019 EPS outlook benefit Fresenius Medical's (FMS) Q2 earnings. However, soft performance at Latin America remains a woe.

NuVasive (NUVA) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research

NuVasive (NUVA) witnesses balanced revenue growth across majority of key operating segments.

QIAGEN (QGEN) Misses Q2 Earnings Estimates, Lowers View

by Zacks Equity Research

QIAGEN (QGEN) registers revenue growth across majority of its geographies in Q2.

PerkinElmer (PKI) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Higher revenues and growth in Diagnostics segment benefit PerkinElmer's (PKI) Q2 earnings. However, forex remains a woe.

Ecolab (ECL) Q2 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Ecolab (ECL) gains from solid segmental contributions in the second quarter. It retains 2019 EPS view.

Will Intuitive Surgical (ISRG) Gain on Rising Earnings Estimates?

by Zacks Equity Research

Intuitive Surgical (ISRG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Intuitive Surgical (ISRG) Q2 Earnings Beat, Guidance Narrowed

by Zacks Equity Research

Intuitive Surgical (ISRG) expects 2019 procedure growth within 16-17%.

Should You Buy Intuitive Surgical (ISRG) Ahead of Earnings?

by Zacks Equity Research

Intuitive Surgical (ISRG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Tracey Ryniec headshot

The 5 Hottest Earnings Charts This Week

by Tracey Ryniec

The 5 stocks have had the sizzle over the last 5 years. Will it continue this week?

Intuitive Surgical to Boost da Vinci Platform With Buyout

by Zacks Equity Research

Intuitive Surgical's (ISRG) acquisition of Scholly Fiberoptic's robotic endoscope business to likely boost the acquirer's da Vinci Surgical system.

Intuitive Surgical (ISRG) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Intuitive Surgical (ISRG) closed the most recent trading day at $526.25, moving -1.82% from the previous trading session.

Can Instruments Drive Intuitive Surgical (ISRG) Q2 Earnings?

by Zacks Equity Research

Intuitive Surgical (ISRG) expects its core Instruments and Accessories unit to boost second-quarter 2019 results.

Urmimala Biswas headshot

Tap AI-Powered Medical Device Stocks as FDA Bolsters SaMD

by Urmimala Biswas

The whole MedTech community finds a reason to cheer over with the FDA's recent proposal for Software as a Medical Device.

Intuitive Surgical (ISRG) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Intuitive Surgical (ISRG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Trina Mukherjee headshot

Medical Products Industry Outlook: Growth Prospects Radiant

by Trina Mukherjee

Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.

Intuitive Surgical (ISRG) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Intuitive Surgical (ISRG) closed at $477.22, marking a +1.12% move from the previous day.

Intuitive Surgical (ISRG) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Intuitive Surgical (ISRG) closed at $476.13, marking a +0.49% move from the previous day.

Intuitive Surgical (ISRG) Down 7.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.